Lyon: Innovent Biologics (01801.HK) reported product revenue in the first half of the year far exceeding expectations, serving as a positive catalyst for its stock price.

According to Zhituo Finance APP, CICC has released a research report stating that Innovent Biologics (01801.HK) announced product revenue of 8.2 billion yuan for the first half of 2026, a year-on-year increase of 55%, far exceeding the market expectation of 6.9 billion yuan. Considering earlier market concerns that anti-corruption measures could hinder the pharmaceutical industry's performance in the first half of the year, this product sales performance is particularly encouraging and is believed to be a positive catalyst for the stock price today.